Clinical Trial Eligibility in Real‐World Alopecia Areata Patients Treated With Baricitinib
Dermatologic Therapy · 2026-01 · 2026 (1)
DOI: 10.1155/dth/1358468 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermatologic Therapy, online erschienen am 20.08.2026. Verfasst von Daniel Muñoz-Barba und 5 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The eligibility criteria applied in baricitinib randomised clinical trials (RCTs) for alopecia areata (AA) may not fully capture the spectrum of patients encountered in routine clinical practice. The aim of this study was to determine the proportion of patients with AA treated with baricitinib in routine clinical practice who would have met RCT eligibility criteria.
Methods
A prospective, observational, single‐centre study was conducted. Patients receiving baricitinib were classified according to whether they fulfilled BRAVE AA’s RCT eligibility criteria. Variables collected were compared between groups.
Results
Forty‐eight patients were included, with a mean age of 36.9 years and a female‐to‐male ratio of 2:1. Overall, only 20.8% of patients fulfilled RCT eligibility criteria, most commonly due to recent use of corticosteroids (62.5%), disease duration (43.8%) and baseline Severity of Alopecia Tool (SALT) score (29.17%). Noneligible patients more frequently had long‐standing disease, whereas eligible patients exhibited higher baseline SALT score and more frequent eyebrow/eyelash involvement ( p < 0.05). Despite these baseline differences, exploratory analyses showed broadly overlapping efficacy and safety trends between groups during follow‐up ( p > 0.10).
Conclusions
This study shows that only a minority of real‐world patients with AA treated with baricitinib would have met the eligibility criteria applied in RCT. Although exploratory analyses revealed broadly overlapping effectiveness and safety trends between eligible and noneligible patients, larger prospective studies are needed to determine whether broader eligibility criteria could improve the representativeness and generalisability of future clinical trials.
Zitieren
APA
Muñoz-Barba, D., Rosa, M. L. D. L., Rodríguez-Sanna, A. I., García-Moronta, C., Sánchez-Díaz, M., & Arias-Santiago, S. (2026). Clinical Trial Eligibility in Real‐World Alopecia Areata Patients Treated With Baricitinib. Dermatologic Therapy, 2026(1). https://doi.org/10.1155/dth/1358468
Vancouver
Muñoz-Barba D, Rosa MLDL, Rodríguez-Sanna AI, García-Moronta C, Sánchez-Díaz M, Arias-Santiago S. Clinical Trial Eligibility in Real‐World Alopecia Areata Patients Treated With Baricitinib. Dermatologic Therapy. 2026;2026(1). doi:10.1155/dth/1358468
BibTeX
@article{MuozBarba2026,
author = {Muñoz-Barba, Daniel and Rosa, Miguel Limeres de la and Rodríguez-Sanna, Andrea Isabel and García-Moronta, Carmen and Sánchez-Díaz, Manuel and Arias-Santiago, Salvador},
title = {Clinical Trial Eligibility in Real‐World Alopecia Areata Patients Treated With Baricitinib},
journal = {Dermatologic Therapy},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/dth/1358468}
}
EUVIMED